Testing a new immune therapy for hard-to-treat lupus

This is a Phase 1 trial testing a new medication called A-319 in people with active or hard-to-treat lupus. A-319 works by activating your body's T cells to target and remove the harmful B cells that produce damaging antibodies in lupus. The study will evaluate how safe this medication is, how your body processes it, and whether it helps control lupus symptoms.

People with lupus often don't respond well to existing treatments, and their condition continues to cause serious inflammation and tissue damage. This medication is being tested to see if it offers a new, more effective way to control the disease by directly targeting the immune cells causing the problem.